These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 21183434)

  • 1. Good manufacturing practice: the role of local manufacturers and competent authorities.
    Tomić S; Filipović Sučić A; Ilić Martinac A
    Arh Hig Rada Toksikol; 2010 Dec; 61(4):425-36. PubMed ID: 21183434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory pathways for vaccines for developing countries.
    Milstien J; Belgharbi L
    Bull World Health Organ; 2004 Feb; 82(2):128-33. PubMed ID: 15042235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmaceutical product quality control and good manufacturing practices].
    Hiyama Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2010; (128):1-16. PubMed ID: 21381389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aid conditionalities, international Good Manufacturing Practice standards and local production rights: a case study of local production in Nepal.
    Brhlikova P; Harper I; Subedi M; Bhattarai S; Rawal N; Pollock AM
    Global Health; 2015 Jun; 11():25. PubMed ID: 26072308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of manufacture--principles and purposes.
    Luff PR
    Dev Biol Stand; 1992; 79():155-8. PubMed ID: 1286749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organization
    World Health Organ Tech Rep Ser; 2005; 929():1-142, backcover. PubMed ID: 16353684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good Manufacturing Practice for Medicinal Products in Bulgaria: an Analysis of Regulatory Inspection Findings.
    Stoimenova AH; Kirilov BJ; Gueorguiev SR; Petkova-Gueorguieva ES; Ognianov SG
    Folia Med (Plovdiv); 2020 Mar; 62(1):165-171. PubMed ID: 32337904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.
    Tauqeer F; Myhr K; Gopinathan U
    Health Policy Plan; 2019 Jul; 34(6):440-449. PubMed ID: 31302684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organization Expert Committee on Specifications for Pharmaceutical Preparations
    World Health Organ Tech Rep Ser; 2003; 908():i-viii, 1-136, back cover. PubMed ID: 12768889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
    J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutual recognition of pharmaceutical good manufacturing practice inspection reports, medical device quality system audit reports, and certain medical device product evaluation reports between the United States and the European Community--FDA. Final rule.
    Fed Regist; 1998 Nov; 63(215):60122-64. PubMed ID: 10187390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assurance of medical device quality with quality management system: an analysis of good manufacturing practice implementation in Taiwan.
    Li TW; Tu PW; Liu LL; Wu SI
    Biomed Res Int; 2015; 2015():670420. PubMed ID: 26075255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early experience of the European Medical Devices Vigilance System.
    Randall H
    Australas Phys Eng Sci Med; 1997 Dec; 20(4):203-6. PubMed ID: 9503691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Accession to the PIC/S and pharmaceutical quality system in Japan].
    Katori N
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):22-35. PubMed ID: 25707200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ISO 9000. Policy implications for FDA. Taking the pulse of increasing global use of the ISO series of uniform quality standards by FDA regulated industries.
    Schwemer WL; Lynch MA
    J Parenter Sci Technol; 1993; 47(3):101-18. PubMed ID: 8360802
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.